{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}],"title":"HU Resistant"},{"measurements":[{"groupId":"OG000","value":"25"}],"title":"HU Intolerant"}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"title":"Week 104"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}],"title":"HU Resistant"},{"measurements":[{"groupId":"OG000","value":"21"}],"title":"HU Intolerant"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"Week 156"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}],"title":"HU Resistant"},{"measurements":[{"groupId":"OG000","value":"18"}],"title":"HU Intolerant"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"Week 208"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}],"title":"HU Resistant"},{"measurements":[{"groupId":"OG000","value":"12"}],"title":"HU Intolerant"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"Week 260"}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"description":"Proportion of patients achieving a Hct control at Week 104 as defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104 and with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8 Endpoint for Week 156, Week 208 and Week 260 were defined, similarly.","groups":[{"description":"Ruxolitinib at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid","id":"OG000","title":"Ruxolitinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Set (FAS) included all participants to whom study treatment was assigned by randomization and had valid measurements for the outcome measure. Data after crossover for participants randomized to BAT were not collected.","reportingStatus":"POSTED","timeFrame":"From Week 8 to Week 104, 156, 208 and 260","title":"Number of Participants Achieving a Hematocrit (Hct) Control at Week 104, Week 156, Week 208 and Week 260.","type":"SECONDARY","unitOfMeasure":"Participants"}